Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Innovation Pharmaceuticals Inc (IPIX) Message Board

Government Shutdown Could Leave Biotech Companies

Message Board Public Reply | Private Reply | Keep | Replies (2)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 72447
(Total Views: 408)
Posted On: 01/26/2019 10:55:22 AM
Posted By: AlanC
Government Shutdown Could Leave Biotech Companies in a Lurch

The longer the U.S. government shutdown drags on, the wider its impact spreads. With the Food and Drug Administration (FDA) running out of funding, that could spell trouble for biotech and pharmaceutical companies seeking approvals for various treatments. Here are three companies facing major obstacles for important projects.

Aimmune Therapeutics (NASDAQ:AIMT) is stuck waiting for the FDA to review its application for a peanut allergy immunotherapy, which the agency announced won't happen until the shutdown ends. If approved, it would be the first therapy of its kind.
Amarin (NASDAQ:AMRN): A recent study showed that Vascepa, an existing treatment for lowering triglyceride levels, could reduce the risk of major cardiovascular events such as heart attack and stroke. The company plans to apply for a label that includes those benefits in the first quarter of 2019, but there's no telling how long approval could take.
Celgene (NASDAQ:CELG) has two drugs potentially in limbo due to the shutdown. The biggest headache would be additional slowdowns for Ozanimod, a treatment for multiple sclerosis that was previously stalled by a filing mistake. It was expected to be one of the biggest new drugs to hit the market.
https://www.fool.com/investing/2019/01/22/3-b...-us-g.aspx
Go IPIX!!!


(2)
(0)




Innovation Pharmaceuticals Inc (IPIX) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us